6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2018

Commission File Number: 001-36596

___________________

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
(Address of principal executive offices)
___________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [   ]      Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[   ]

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Trillium Therapeutics Inc.
Date: June 5, 2018
	By:     /s/ James Parsons
	Name: James Parsons
	Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description
99.1	Report of Voting Results
99.2	News Release dated June 5, 2018

EX-99.1

June 1, 2018

British Columbia Securities Commission
Alberta Securities Commission
The Manitoba Securities Commission
Ontario Securities Commission
Nova Scotia Securities Commission

Via Sedar

NOTICE PURSUANT TO SUBSECTION 11.3 OF
NATIONAL INSTRUMENT 51-102 (“NI 51-102”)
CONTINUOUS DISCLOSURE OBLIGATIONS

Pursuant to the requirements set out in subsection 11.3 of NI 51-102, the undersigned hereby gives notice of the results of voting from the June 1, 2018 Annual and Special Meeting (the “Meeting”) of shareholders of Trillium Therapeutics Inc. (the “Corporation”).

1.           Election of Directors

The shareholders of the Corporation voted by ballot to elect the following individuals as directors of the Corporation until the next annual meeting of shareholders or until their successors are elected or appointed, as follows:

Name	Votes in Favour	% Votes in Favour	Votes Withheld	% Votes Withheld
Mr. Luke Beshar	5,071,936	98.89	56,904	1.11
Dr. Robert Kirkman	5,071,906	98.89	56,934	1.11
Dr. Michael Moore	5,072,821	98.91	56,019	1.09
Dr. Thomas Reynolds	5,071,906	98.89	56,934	1.11
Dr. Niclas Stiernholm	5,072,479	98.90	56,361	1.10
Dr. Calvin Stiller	5,073,051	98.91	55,789	1.09
Dr. Helen Tayton-Martin	5,073,252	98.92	55,588	1.08

2.           Appointment of Auditors

The shareholders of the Corporation voted, on a show of hands, to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year and authorize the directors to fix their remuneration.

3.           Approval of 2018 Stock Option Plan

The shareholders of the Corporation voted by ballot to approve the Corporation’s amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting. The voting results were as follows:

Votes in Favour	% Votes in Favour	Votes Against	% Votes Against
3,897,219	76.81	1,176,621	23.19

EX-99.2

FOR IMMEDIATE RELEASE	NASDAQ:TRIL
	TSX: TRIL

TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO, June 5, 2018 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 1, 2018. The results of the director elections were as follows:

Name	Votes in Favor	% Votes in Favor	Votes Withheld	% Votes Withheld
Mr. Luke Beshar	5,071,936	98.89	56,904	1.11
Dr. Robert Kirkman	5,071,906	98.89	56,934	1.11
Dr. Michael Moore	5,072,821	98.91	56,019	1.09
Dr. Thomas Reynolds	5,071,906	98.89	56,934	1.11
Dr. Niclas Stiernholm	5,072,479	98.90	56,361	1.10
Dr. Calvin Stiller	5,073,051	98.91	55,789	1.09
Dr. Helen Tayton-Martin	5,073,252	98.92	55,588	1.08

The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year, and approved the Corporation’s 2018 Stock Option Plan.

Retiring director Dr. Henry Friesen appointed Director Emeritus

Trillium is pleased to announce the appointment of Dr. Henry Friesen as Director Emeritus. Dr. Calvin Stiller, Chair of the Board of Directors, commented on Dr. Friesen’s retirement from the Board of Directors. “Dr. Friesen, who is one of the most celebrated living Canadian physicians and scientists, responsible for such extraordinary accomplishments as discovering prolactin, and founding the Canadian Institutes of Health Research and Genome Canada, has honored us by being a director of the company for the past 7 years. We have benefited from his wisdom and commitment to integrity and in recognition of his contribution we have created the honorific position of Director Emeritus which Dr. Friesen has kindly accepted. We thank him for his extraordinary service to the company.”

About Trillium Therapeutics:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-621 has recently been granted an Orphan Drug Designation by the FDA for the treatment of cutaneous T-cell lymphoma. TTI-622, an IgG4 SIRPaFc protein which is primarily being developed for combination therapy, is expected to begin clinical testing in 2018. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: www.trilliumtherapeutics.com

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Contact:
Trillium Therapeutics Inc.
James Parsons
Chief Financial Officer
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com

Investor and Media Relations:
Jessica Dyas
Canale Communications for Trillium Therapeutics
619-849-5385
jessica@canalecomm.com

-2-